255 related articles for article (PubMed ID: 16285718)
1. Isolation and characterization of the B-cell marker CD20.
Ernst JA; Li H; Kim HS; Nakamura GR; Yansura DG; Vandlen RL
Biochemistry; 2005 Nov; 44(46):15150-8. PubMed ID: 16285718
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide.
Du J; Wang H; Zhong C; Peng B; Zhang M; Li B; Hou S; Guo Y; Ding J
Mol Immunol; 2008 May; 45(10):2861-8. PubMed ID: 18346788
[TBL] [Abstract][Full Text] [Related]
3. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
[TBL] [Abstract][Full Text] [Related]
4. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
Davis TA; Czerwinski DK; Levy R
Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
[TBL] [Abstract][Full Text] [Related]
5. [One amino acid mutation in an anti-CD20 antibody fragment that affects the yield bacterial secretion and the affinity].
Liu YX; Xiong DS; Fan DM; Shao XF; Xu YF; Zhu ZP; Yang CZ
Sheng Wu Gong Cheng Xue Bao; 2003 May; 19(3):272-6. PubMed ID: 15969005
[TBL] [Abstract][Full Text] [Related]
6. A CD20 tandem-epitope immunogen elicits antibody in mice that binds murine cell surface CD20 and depletes splenic B cells in vivo.
Oscherwitz J; Gribbin TE; Cease KB
Mol Immunol; 2010 Apr; 47(7-8):1484-91. PubMed ID: 20189250
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking.
Unruh TL; Li H; Mutch CM; Shariat N; Grigoriou L; Sanyal R; Brown CB; Deans JP
Immunology; 2005 Oct; 116(2):223-32. PubMed ID: 16162271
[TBL] [Abstract][Full Text] [Related]
8. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.
Janas E; Priest R; Wilde JI; White JH; Malhotra R
Clin Exp Immunol; 2005 Mar; 139(3):439-46. PubMed ID: 15730389
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD20 treatments and the lymphocyte membrane: pathology for therapy.
Borisch B; Semac I; Soltermann A; Palomba C; Hoessli DC
Verh Dtsch Ges Pathol; 2001; 85():161-6. PubMed ID: 11894393
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a peptide ELISA for the detection of rituximab in serum.
Blasco H; Lalmanach G; Godat E; Maurel MC; Canepa S; Belghazi M; Paintaud G; Degenne D; Chatelut E; Cartron G; Le Guellec C
J Immunol Methods; 2007 Aug; 325(1-2):127-39. PubMed ID: 17651747
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
Liu Y; Zheng M; Lai Z; Xiong D; Fan D; Xu Y; Peng H; Shao X; Xu Y; Yang M; Wang J; Liu H; Xie Y; Yang C; Zhu Z
Cancer Lett; 2004 Mar; 205(2):143-53. PubMed ID: 15036646
[TBL] [Abstract][Full Text] [Related]
12. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
13. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.
Maloney DG
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S19-26. PubMed ID: 15786022
[TBL] [Abstract][Full Text] [Related]
14. CD20 as a target for therapeutic type I and II monoclonal antibodies.
Beers SA; Chan CH; French RR; Cragg MS; Glennie MJ
Semin Hematol; 2010 Apr; 47(2):107-14. PubMed ID: 20350657
[TBL] [Abstract][Full Text] [Related]
15. Mimotope vaccination for epitope-specific induction of anti-CD20 antibodies.
Li M; Yan Z; Han W; Zhang Y
Cell Immunol; 2006 Feb; 239(2):136-43. PubMed ID: 16814270
[TBL] [Abstract][Full Text] [Related]
16. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
Golay J; Cittera E; Di Gaetano N; Manganini M; Mosca M; Nebuloni M; van Rooijen N; Vago L; Introna M
Haematologica; 2006 Feb; 91(2):176-83. PubMed ID: 16461301
[TBL] [Abstract][Full Text] [Related]
17. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Smith MR
Oncogene; 2003 Oct; 22(47):7359-68. PubMed ID: 14576843
[TBL] [Abstract][Full Text] [Related]
18. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
20. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma.
Jubala CM; Wojcieszyn JW; Valli VE; Getzy DM; Fosmire SP; Coffey D; Bellgrau D; Modiano JF
Vet Pathol; 2005 Jul; 42(4):468-76. PubMed ID: 16006606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
